Latest Breaking News On - Early diffuse cutaneous systemic - Page 1 : comparemela.com

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

United statesTheresa podrebaracMartin kolbMcmaster universityHorizon therapeuticsAnnounces first patient enrolledPivotal trial evaluatingIdiopathic pulmonary fibrosisIrelandi januaryMinute walk testBrief interstitial lung diseaseEarly diffuse cutaneous systemicSmall moleculeNew chemical entityDrug deliveryFlow release